What's New in Migraine Prevention? Understanding the 2026 AAN/AHS Guidelines
From Neurology: Disease Deep Dive · 20:28
Show by Practical Neurology
Andrew Blumenfeld, MD, Cedars-Sinai Neurology, Los Angeles, CA, discusses the updated American Academy of Neurology and American Headache Society guideline on preventive migraine therapy, including the growing emphasis on shared decision-making, the role of CGRP-targeted therapies, and balancing efficacy with tolerability. He also examines how clinicians can assess meaningful treatment response beyond migraine frequency and explores emerging approaches to prevention, including combination therapies and novel therapeutic targets. Reference: Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Headache. 2026;66(9):2173-2184. doi:10.1111/head.70199
More episodes of Neurology: Disease Deep Dive
More episodes
- Fenfluramine for Lennox-Gastaut Syndrome: Long-Term Efficacy, Safety, and Outcomes Beyond Seizure Reduction
- Rethinking Multiple Sclerosis: A New Biologic Framework for MS Progression
- Narcolepsy, Idiopathic Hypersomnia, and General Sleep Disorders
- NMOSD Part 1 - Overview and important considerations for diagnosis
- NMOSD Part 2 - The importance and tools for monitoring NMOSD, and signs, symptoms and evaluation of disease activity
- NMOSD Part 3 - Overview of treatment, including goals, triggers, and considerations for switching therapies
- Advances in the Evaluation of TBI
- The Evolving Therapeutic Landscape for Parkinson Disease
- Cerebrovascular Inflammatory Conditions: Diagnostic Challenges and Treatment Considerations
- Advances in ALS: New Targets, Trials, and Care Strategies
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.